Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
Sign Up to like & getrecommendations! Published in 2018 at "The Lancet Neurology"
DOI: 10.1016/s1474-4422(18)30039-5
Abstract: BACKGROUND Pimavanserin is a selective 5-HT2A receptor inverse agonist and antagonist approved in the USA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. No safe or effective pharmacological treatment is approved… read more here.
Keywords: alzheimer disease; pimavanserin versus; versus placebo; placebo ... See more keywords